Epidermal growth factor receptor (EGFR)-activating mutations represent the most frequent targetable alteration with a prevalence of nearly 20% in Caucasians with lung adenocarcinomas (ADCs) and show sensitivity to various TKIs.3 The gene discussed is EGFR; the disease is lung adenocarcinoma.